NKTX:NASDAQNkarta, Inc. Analysis
Data as of 2026-05-21 - not real-time
$3.03
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Nkarta is trading just above its near‑term support level, with the 20‑day SMA comfortably above the 50‑day SMA, suggesting a bullish price bias despite a bearish MACD histogram and a neutral RSI. Volatility is extreme (30‑day >100%) and beta is well above market, flagging pronounced price swings, while volume trends are weakening. The company has no revenue and negative earnings, yet its price‑to‑book sits under 1.0 and analyst consensus is a strong‑buy with a median price target of $11, implying a >200% upside. Material clinical progress is evident from ongoing enrollment at high cell‑dose regimens across multiple autoimmune indications, bolstered by a CRISPR Therapeutics partnership.
Cash on hand exceeds debt, providing a runway for continued trial activity, but the balance sheet is thin and free cash flow remains negative. The combination of a deep‑discount valuation, high growth potential, and substantial execution risk makes the stock attractive for investors comfortable with biotech volatility.
Cash on hand exceeds debt, providing a runway for continued trial activity, but the balance sheet is thin and free cash flow remains negative. The combination of a deep‑discount valuation, high growth potential, and substantial execution risk makes the stock attractive for investors comfortable with biotech volatility.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with bullish SMA crossover
- Bearish MACD signal and decreasing volume
- High short‑term volatility and beta
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong analyst consensus and >200% upside to median target
- Ongoing high‑dose enrollment across multiple indications
- Undervalued price‑to‑book relative to peers
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Potential of CAR‑NK platform to address unmet autoimmune markets
- Strategic collaboration with CRISPR Therapeutics
- Sufficient cash runway to fund continued clinical development
Key Metrics & Analysis
Financial Health
P/E Ratio-1.8
ROE-30.07%
ROA-17.10%
Debt/Equity26.24
P/B Ratio0.7
Op. Cash Flow$-87286000
Free Cash Flow$-57381500
Industry P/E27.3
Technical Analysis
TrendBullish
RSI55.4
Support$2.59
Resistance$3.35
MA 20$2.94
MA 50$2.63
MA 200$2.24
MACDBearish
VolumeDecreasing
Fear & Greed Index91.5
Valuation
Target Price$11.20
Upside/Downside269.64%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.13
Volatility105.30%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.